Imugene Limited Stock Analysis
| IUGNF Stock | USD 0.18 0.02 10.00% |
Imugene Limited holds a debt-to-equity ratio of 0.004. Imugene's financial risk is the risk to Imugene stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Imugene's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Imugene's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Imugene Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Imugene's stakeholders.
For many companies, including Imugene, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Imugene Limited, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Imugene's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Imugene's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Imugene is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Imugene to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Imugene is said to be less leveraged. If creditors hold a majority of Imugene's assets, the Company is said to be highly leveraged.
Imugene Limited is overvalued with Real Value of 0.17 and Hype Value of 0.18. The main objective of Imugene pink sheet analysis is to determine its intrinsic value, which is an estimate of what Imugene Limited is worth, separate from its market price. There are two main types of Imugene's stock analysis: fundamental analysis and technical analysis.
The Imugene pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Imugene's ongoing operational relationships across important fundamental and technical indicators.
Imugene |
Imugene Pink Sheet Analysis Notes
About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.0. Imugene Limited had not issued any dividends in recent years. The entity had 2:15 split on the 12th of November 2002. Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Imugene is traded on OTC Exchange in the United States.The quote for Imugene Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Imugene Limited call Leslie Chong at 61 3 9824 5254 or check out https://www.imugene.com.Imugene Limited Investment Alerts
| Imugene Limited had very high historical volatility over the last 90 days | |
| Imugene Limited has some characteristics of a very speculative penny stock | |
| Imugene Limited has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.97 M. Net Loss for the year was (37.87 M) with profit before overhead, payroll, taxes, and interest of 12.97 M. | |
| Imugene Limited has accumulated about 99.89 M in cash with (30.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Cabaletta Bio to Participate in Guggenheim Emerging Outlook Biotech Summit 2026 - Quiver Quantitative |
Imugene Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 642.17 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Imugene's market, we take the total number of its shares issued and multiply it by Imugene's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Imugene Profitablity
The company has Profit Margin (PM) of (2.92) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.91) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.91.Technical Drivers
As of the 17th of February 2026, Imugene retains the Risk Adjusted Performance of 0.0149, downside deviation of 9.55, and Market Risk Adjusted Performance of (0.04). Imugene technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Imugene Limited information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Imugene is priced fairly, providing market reflects its last-minute price of 0.18 per share. As Imugene Limited appears to be a penny stock we also urge to confirm its total risk alpha numbers.Imugene Limited Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Imugene middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Imugene Limited. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Imugene Predictive Daily Indicators
Imugene intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Imugene pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 0.9 | |||
| Day Median Price | 0.18 | |||
| Day Typical Price | 0.18 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) |
Imugene Forecast Models
Imugene's time-series forecasting models are one of many Imugene's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Imugene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Imugene Limited Debt to Cash Allocation
Many companies such as Imugene, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Imugene Limited has accumulated 673.43 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Imugene Limited has a current ratio of 15.01, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Imugene until it has trouble settling it off, either with new capital or with free cash flow. So, Imugene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imugene Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imugene to invest in growth at high rates of return. When we think about Imugene's use of debt, we should always consider it together with cash and equity.Imugene Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Imugene's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Imugene, which in turn will lower the firm's financial flexibility.About Imugene Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Imugene prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Imugene shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Imugene. By using and applying Imugene Pink Sheet analysis, traders can create a robust methodology for identifying Imugene entry and exit points for their positions.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Imugene is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Imugene to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Balance Of Power Now
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios |
| All Next | Launch Module |
Complementary Tools for Imugene Pink Sheet analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |